BIOA and BIOAB Related Headlines
Go Back- More than 75% of Leqembi®-treated patients remained stable and nearly 7% improved over an average of 17 months of treatment in real-world LEADER study data presented at AAIC® 2026
- FDA clears Leqembi Iqlik subcutaneous shot as Alzheimer's start dose
- FDA approves Leqembi Iqlik® (lecanemab-irmb) subcutaneous injection as a starting dose for early Alzheimer's disease
- New clinical data on the Leqembi® subcutaneous autoinjector presented at AAIC® 2026 support similar efficacy and safety to IV formulation in early Alzheimer's disease
- Number of shares and votes in BioArctic AB (publ) as of May 29, 2026
- Bulletin from the Annual General Meeting in BioArctic AB (publ)
- BioArctic publishes the Annual Report and Sustainability Report for 2025
- New data on long-term, real-world treatment with lecanemab presented at the 2026 AD/PD™ congress
- Number of shares and votes in BioArctic AB (publ) as of February 27, 2026
- Invitation to presentation of BioArctic's fourth quarter report for October - December 2025 on February 18 at 9.30 a.m. CET
- Leqembi included in China's commercial insurance innovative drug list
- New data on lecanemab to be presented at CTAD conference
- Leqembi® approved for IV maintenance treatment in the United Kingdom
- Leqembi® Iqlik™ (lecanemab-irmb) maintenance treatment launched in the U.S.
- Leqembi® approved for IV maintenance treatment in China
- BioArctic signs $30 million deal with Novartis for brain drug technology
- BioArctic and Novartis sign an option, collaboration and license agreement using BrainTransporter™ for an upfront payment of USD 30 million plus additional potential milestones and royalties
- Leqembi® (lecanemab) launched in the EU today
- Sales of Leqembi® totaled 23.1 billion yen in the second quarter 2025
- BioArtic: Latest data presented at AAIC 2025 reinforces lecanemab's clinical effect with consistent safety profile
- Lecanemab four-year efficacy and safety data to be presented at AAIC 2025
BIOA and BIOAB Related Press Releases
Go Back- More than 75% of Leqembi®-treated patients remained stable and nearly 7% improved over an average of 17 months of treatment in real-world LEADER study data presented at AAIC® 2026
- FDA approves Leqembi Iqlik® (lecanemab-irmb) subcutaneous injection as a starting dose for early Alzheimer's disease
- New clinical data on the Leqembi® subcutaneous autoinjector presented at AAIC® 2026 support similar efficacy and safety to IV formulation in early Alzheimer's disease
- Number of shares and votes in BioArctic AB (publ) as of May 29, 2026
- Bulletin from the Annual General Meeting in BioArctic AB (publ)
- BioArctic publishes the Annual Report and Sustainability Report for 2025
- New data on long-term, real-world treatment with lecanemab presented at the 2026 AD/PD™ congress
- Number of shares and votes in BioArctic AB (publ) as of February 27, 2026
- Invitation to presentation of BioArctic's fourth quarter report for October - December 2025 on February 18 at 9.30 a.m. CET
- Leqembi included in China's commercial insurance innovative drug list
- New data on lecanemab to be presented at CTAD conference
- Leqembi® approved for IV maintenance treatment in the United Kingdom
- Leqembi® Iqlik™ (lecanemab-irmb) maintenance treatment launched in the U.S.
- Leqembi® approved for IV maintenance treatment in China
- BioArctic and Novartis sign an option, collaboration and license agreement using BrainTransporter™ for an upfront payment of USD 30 million plus additional potential milestones and royalties
- Leqembi® (lecanemab) launched in the EU today
- Sales of Leqembi® totaled 23.1 billion yen in the second quarter 2025
- BioArtic: Latest data presented at AAIC 2025 reinforces lecanemab's clinical effect with consistent safety profile
- Lecanemab four-year efficacy and safety data to be presented at AAIC 2025
